DNA Link Inc (127120) - Total Liabilities
Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩53.95 Billion KRW (≈ $36.56 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 127120 long-term investment intensity to see how much of total assets are deployed in long-term investments.
DNA Link Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of DNA Link Inc.
DNA Link Inc Competitors by Total Liabilities
The table below lists competitors of DNA Link Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
|
USA | $354.24 Million |
|
ZYLOX-TONBRDG.MED.TECH.H1
F:818
|
Germany | €341.97 Million |
|
Bergman & Beving AB (publ)
ST:BERG-B
|
Sweden | Skr4.41 Billion |
|
Fuxin Dare Automotive Parts Co Ltd
SHE:300473
|
China | CN¥2.80 Billion |
|
Wuhan LinControl Automotive Electronics Co. Ltd. A
SHG:688667
|
China | CN¥386.49 Million |
|
Shandong Huatai Paper Industry Shareholding Co Ltd
SHG:600308
|
China | CN¥6.74 Billion |
|
Shenzhen Grandland Decoration Group Co Ltd
SHE:002482
|
China | CN¥2.32 Billion |
|
Shenzhen Jieshun Science and Technology Industry Co Ltd
SHE:002609
|
China | CN¥1.43 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See DNA Link Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DNA Link Inc (2011–2025)
The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩54.44 Billion ≈ $36.90 Million |
+85.46% |
| 2024-12-31 | ₩29.36 Billion ≈ $19.89 Million |
+135.23% |
| 2023-12-31 | ₩12.48 Billion ≈ $8.46 Million |
-20.09% |
| 2022-12-31 | ₩15.62 Billion ≈ $10.58 Million |
+89.40% |
| 2021-12-31 | ₩8.25 Billion ≈ $5.59 Million |
-40.42% |
| 2020-12-31 | ₩13.84 Billion ≈ $9.38 Million |
-14.77% |
| 2019-12-31 | ₩16.24 Billion ≈ $11.00 Million |
+5.02% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.48 Million |
+996.65% |
| 2017-12-31 | ₩1.41 Billion ≈ $955.48K |
-94.14% |
| 2016-12-31 | ₩24.04 Billion ≈ $16.29 Million |
+11.69% |
| 2015-12-31 | ₩21.53 Billion ≈ $14.59 Million |
+68.92% |
| 2014-12-31 | ₩12.74 Billion ≈ $8.64 Million |
+3.34% |
| 2012-12-31 | ₩12.33 Billion ≈ $8.36 Million |
+37.43% |
| 2011-12-31 | ₩8.97 Billion ≈ $6.08 Million |
-- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more